New combo infusion aims to tame Opioid-Resistant cancer pain
NCT ID NCT07408193
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This early-phase trial tests whether combining lidocaine and ketamine can reduce severe cancer-related pain that doesn't respond to opioids. Twenty-four adults will receive two weekly infusions of the drug combination or an active placebo in a blinded, crossover design. The goal is to see if this approach provides better pain relief than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID-REFRACTORY CHRONIC CANCER-RELATED PAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University General Hospital of Athens "Attikon" - National and Kapodistrian University of Athens Medical School
RECRUITINGAthens, Attica, 12461, Greece